Johnson & Johnson Tremfya — Percent Change (as a percent) increased by 618.9% to 68.3% in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 275.3%, from 18.2% to 68.3%. Over 2 years (FY 2021 to FY 2025), Tremfya — Percent Change (as a percent) shows a downward trend with a -19.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
A positive percentage change indicates accelerating demand or successful market expansion, whereas a negative change suggests slowing growth, market saturation, or competitive displacement.
This metric measures the period-over-period growth rate of net sales for a specific pharmaceutical product line. It serv...
Comparable to year-over-year or quarter-over-quarter revenue growth rates for individual blockbuster drugs at peer pharmaceutical firms.
jnj_segment_tremfya_percent_change_as_a_percent| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 40.2% | 64.1% | 9.4% | 41.3% | 24.4% | 35.9% | 8.4% | 18.3% | 22.2% | 1.1% | 26.3% | 28.3% | 13% | 18.2% | 31% | 41.3% | 9.5% | 68.3% |
| QoQ Change | — | +59.5% | -85.3% | +339.4% | -40.9% | +47.1% | -76.6% | +117.9% | +21.3% | -95.0% | >999% | +7.6% | -54.1% | +40.0% | +70.3% | +33.2% | -77.0% | +618.9% |
| YoY Change | — | — | — | — | -39.3% | -44.0% | -79.7% | -25.0% | -38.2% | — | +213.1% | +54.6% | -41.4% | -30.8% | +9.5% | +217.7% | — | +275.3% |